Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
OPK
OPK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OPK News
OPKO Health to Participate in 44th Annual J.P. Morgan Healthcare Conference
Jan 06 2026
Globenewswire
Reasons to Keep OPKO Health Stock in Your Portfolio at This Time
Dec 09 2025
NASDAQ.COM
Insider Buying Update for Friday, November 21: GLOO, OPK
Nov 21 2025
NASDAQ.COM
NextPlat Reports Third Quarter 2025 Results
Nov 13 2025
PRnewswire
Jefferies Lowers OPKO Health Rating to Hold and Reduces Price Target to $1.6
Oct 31 2025
Benzinga
OPKO Health (OPK) Q3 Earnings Review: Analyzing Key Metrics Against Estimates
Oct 30 2025
NASDAQ.COM
ModeX Therapeutics, a subsidiary of OPKO Health, Launches Clinical Trial for MDX2004 Targeting Advanced Cancers
Oct 28 2025
Newsfilter
LH Stock Increases Following Acquisition of Select Assets from BioReference Health
Sep 17 2025
NASDAQ.COM
Labcorp Finalizes Purchase of Key Assets from BioReference Health's Oncology and Clinical Testing Services
Sep 15 2025
Newsfilter
Tuesday 8/12 Insider Buying Report: LINE, OPK
Aug 12 2025
NASDAQ.COM
OPKO Health (OPK) Q2 2025 Earnings Call Transcript
Aug 07 2025
NASDAQ.COM
RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment.
Aug 06 2025
Barron's
Validea Kenneth Fisher Strategy Daily Upgrade Report - 8/1/2025
Aug 01 2025
NASDAQ.COM
Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics
Aug 01 2025
NASDAQ.COM
OPKO Health outlines $640M–$660M 2025 revenue target as BioReference sale and pipeline advances drive profitability push
Jul 31 2025
SeekingAlpha
NextPlat Issues Interim CEO Update Shareholder Letter
Jun 30 2025
PRnewswire
Show More News
